Cigarette and E-Cigarettes Dual Users, Exclusive Users and COVID-19: Findings from Four UK Birth Cohort Studies
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Measures
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019: Offer Help to Quit Tobacco Use; World Health Organization: Geneva, Switzerland, 2019. [Google Scholar]
- Guan, W.-J.; Ni, Z.-Y.; Hu, Y.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.-L.; Hui, D.S.C.; et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef]
- Grundy, E.J.; Suddek, T.; Filippidis, F.T.; Majeed, A.; Coronini-Cronberg, S. Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice. Tob. Induc. Dis. 2020, 18, 58. [Google Scholar] [CrossRef]
- Vardavas, C.I.; Nikitara, K. COVID-19 and smoking: A systematic review of the evidence. Tob. Induc. Dis. 2020, 18, 20. [Google Scholar] [CrossRef] [PubMed]
- Patanavanich, R.; Glantz, S.A. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine Tob. Res. 2020, 22, 1653–1656. [Google Scholar] [CrossRef]
- Zhao, Q.; Meng, M.; Kumar, R.; Wu, Y.; Huang, J.; Lian, N.; Deng, Y.; Lin, S. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 2020, 92, 1915–1921. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, Z.; Peng, F.; Xu, B.; Zhao, J.; Liu, H.; Peng, J.; Li, Q.; Jiang, C.; Zhou, Y.; Liu, S.; et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect. 2020, 81, e16–e25. [Google Scholar] [CrossRef] [PubMed]
- Wenzl, T. Smoking and COVID-19: Did we overlook representativeness? Tob. Induc. Dis. 2020, 18, 1–2. [Google Scholar] [CrossRef] [PubMed]
- Münzel, T.; Hahad, O.; Kuntic, M.; Keaney, J.F., Jr.; Deanfield, J.E.; Daiber, A. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur. Heart J. 2020, 41, 4057–4070. [Google Scholar] [CrossRef]
- Purkayastha, A.; Sen, C.; Garcia, G., Jr.; Langerman, J.; Shia, D.W.; Meneses, L.K.; Vijayaraj, P.; Durra, A.; Koloff, C.R.; Freund, D.R.; et al. Direct Exposure to SARS-CoV-2 and Cigarette Smoke Increases Infection Severity and Alters the Stem Cell-Derived Airway Repair Response. Cell Stem Cell 2020, 27, 869–875.e864. [Google Scholar] [CrossRef]
- The Lancet Respiratory, M. The EVALI outbreak and vaping in the COVID-19 era. Lancet Respir. Med. 2020, 8, 831. [Google Scholar] [CrossRef]
- Rodriguez, J.A.; Roa, A.A.; Lemos-Ramirez, J.C. E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) Mimicking COVID-19 Disease. Case Rep. Pulmonol. 2020, 2020, 8821289. [Google Scholar] [CrossRef]
- World Health Organization. Smoking and COVID-19; World Health Organization: Geneva, Switzerland, 2000; Available online: https://apps.who.int/iris/rest/bitstreams/1285119/retrieve (accessed on 30 June 2020).
- National Center for Chronic Disease, P.; Health Promotion Office on, S. Health. Reports of the Surgeon General. In The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2014. [Google Scholar]
- Gaiha, S.M.; Cheng, J.; Halpern-Felsher, B. Association Between Youth Smoking, Electronic Cigarette Use, and COVID-19. J. Adolesc. Health 2020, 67, 519–523. [Google Scholar] [CrossRef] [PubMed]
- Camacho, O.M.; Murphy, J.J. In Response to “Association Between Youth Smoking, Electronic Cigarette Use, and COVID-19”. J. Adolesc. Health 2021, 68, 214. [Google Scholar] [CrossRef] [PubMed]
- Rich, J.J.; Sussman, R.A. Gaiha et al. Response. J. Adolesc. Health 2021, 68, 215–216. [Google Scholar] [CrossRef] [PubMed]
- Farsalinos, K.; Niaura, R. E-Cigarette Use and COVID-19: Questioning Data Reliability. J. Adolesc. Health 2021, 68, 213. [Google Scholar] [CrossRef] [PubMed]
- Brown, M.; Goodman, A.; Peters, A.; Ploubidis, G.B.; Sanchez, A.; Silverwood, R.K.S. COVID-19 Survey in Five National Longitudinal Studies: Wave 1 User Guide; Version 1; UCL Centre for Longitudinal Studies and MRC Unit for Lifelong Health and Ageing: London, UK, 2020. [Google Scholar]
- Rose, D.; Pevalin, D. A Researcher’s Guide to the National Statistics Socio-Economic Classification; SAGE: New York, NY, USA, 2003; Volume 52. [Google Scholar]
- Jackson, S.E.; Brown, J.; Shahab, L.; Steptoe, A.; Fancourt, D. COVID-19, smoking and inequalities: A study of 53 002 adults in the UK. Tobacco Control 2020. [Google Scholar] [CrossRef]
- Simons, D.; Shahab, L.; Brown, J.; Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 7). Addiction 2020. [Google Scholar] [CrossRef]
- Burström, B.; Tao, W. Social determinants of health and inequalities in COVID-19. Eur. J. Public Health 2020, 30, 617–618. [Google Scholar] [CrossRef] [PubMed]
- Seitz, C.M.; Staley, M.E.; Kearley, J.; Wright, L.; Bowman, R.; Phillips, C.; Orsini, M.M. E-cigarette sharing behavior among college students: An exploratory study. J. Am. Coll. Health 2020, 1–4. [Google Scholar] [CrossRef]
- Wang, X.; Zhang, X.; Xu, X.; Gao, Y. Electronic cigarette use and smoking cessation behavior among adolescents in China. Addict. Behav. 2018, 82, 129–134. [Google Scholar] [CrossRef]
- Rich, Z.C.; Xiao, S. Tobacco as a social currency: Cigarette gifting and sharing in China. Nicotine Tob. Res. 2012, 14, 258–263. [Google Scholar] [CrossRef] [PubMed]
- Paul, C.; Tzelepis, F.; Bisquera, A.; Noble, N.; Wiggers, J. Just how high-risk are ongoing smokers? Exploring clusters of health risk behaviours among current and ex-smokers. Prev. Med. 2016, 93, 70–75. [Google Scholar] [CrossRef] [PubMed]
- Kale, D.; Stautz, K.; Cooper, A. Impulsivity related personality traits and cigarette smoking in adults: A meta-analysis using the UPPS-P model of impulsivity and reward sensitivity. Drug Alcohol Depend. 2018, 185, 149–167. [Google Scholar] [CrossRef] [PubMed]
Weighted Percentages (%) with 95% Confidence Interval | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Millennium Cohort Study (MCS), Born in 2000–2002 (Aged 18–20) (N = 2403) | Next Steps (NEXT), Born in 1989–1990 (Aged 31) (N = 1780) | British Cohort Study (BCS70), Born in 1970 (Aged 51) (N = 4022) | |||||||||||||
Non-Users (N = 1983) | Cigarette (N = 274) | E-cigarette (N = 65) | Dual user (N = 81) | p-Value † | Non-Users (N = 1477) | Cigarette (N = 182) | E-cigarette (N = 74) | Dual user (N = 47) | p-Value † | Non-Users (N = 3330) | Cigarette (N = 398) | E-cigarette (N = 203) | Dual user (N = 91) | p-Value † | |
Overall | 78.0 (74.9–80.8) | 13.7 (11.6–16.1) | 3.5 (2.5–5.1) | 4.7 (3.4–6.5) | 75.5 (71.7–79.0) | 14.3 (11.5–17.6) | 5.8 (4.0–8.2) | 4.4 (2.8–6.8) | 75.5 (74.1–76.8) | 15.2 (14.2–16.4) | 6.5 (5.8–7.3) | 2.8 (2.3–3.3) | |||
Participant characteristics | |||||||||||||||
Gender | |||||||||||||||
Male | 48.0 (44.4–51.6) | 50.7 (42.3–59.1) | 51.1 (33.1–68.8) | 64.8 (49.7–77.4) | 0.001 | 44.3 (40.0–48.6) | 35.6 (25.8–46.7) | 47.0 (29.7–65.0) | 61.6 (40.1–79.4) | 0.14 | 49.1 (47.4–50.8) | 53.7 (48.7–58.5) | 63.9 (57.0–70.2) | 44.84 (34.9–55.2) | <0.01 |
Female | 52.0 (48.4–55.6) | 49.3 (40.9–57.7) | 48.9 (31.2–66.9) | 35.2 (22.6–50.3) | 55.7 (51.4–60.0) | 64.5 (53.3–74.2) | 53.0 (35–70.3) | 38.4 (20.6–59.9) | 50.9 (49.2–52.6) | 46.3 (41.5–51.3) | 36.1 (29.8–43.0) | 55.16 (44.8–65.1) | |||
Socioeconomic Class a | |||||||||||||||
High | 4.0 (2.4–6.5) | 5.3 (1.4–14.4) | 4.52 (0.9–13.7) | 6.1 (2.1–14.5) | <0.001 | 54.8 (50.7–58.8) | 29.8 (21.2–40.1) | 34.4 (21.2–50.5) | 44.0 (24.1–66.0) | 0.00 | 44.0 (42.3–45.7) | 29.1 (24.9–33.8) | 28.7 (22.8–35.3) | 18.0 (11.3–27.3) | <0.001 |
Intermediate | 6.8 (5.4–8.45) | 8.4 (5.1–13.4) | 10.9 (3.6–26.1) | 3.7 (0.5–12.2 | 19.3 (16.3–22.7) | 24.5 (14.6–38.0) | 33.2 (17.1–54.4) | 12.8 (5.1–27.3) | 20.7 (19.3–22.1) | 14.8 (11.7–18.7) | 14.8 (10.5–20.4) | 15.9 (9.6–25.0) | |||
Lower | 18.4 (15.3–22.0) | 32.9 (25.9–40.7) | 29.8 (16.0–48.5) | 33.6 (20.7–49.5) | 14.3 (11.6–17.4) | 23.0 (15.3–33.0) | 23.2 (10.4–43.4) | 32.3 (15–56.2) | 19.09 (17.8–20.5) | 33.4 (28.9–38.2) | 31.3 (25.2–38.0) | 38.1 (28.7–48.5) | |||
Not classifiable § | 70.9 (66.5–74.8) | 53.5 (45.6–61.2) | 54.8 (36.5–71.9) | 56.6 (39.7–72.1) | 11.7 (9.5–14.3) | 22.7 (14.4–33.9) | 9.2 (2.7–23.4) | 10.9 (3.5–26.3) | 16.23 (15–17.5) | 22.7 (18.8–27.1) | 25.3 (19.8–31.7) | 28.1 (19.8–38.2) | |||
Self-rated Health | |||||||||||||||
Excellent | 17.1 (14.7–19.6) | 4.5 (2.3–8.5) | 16.0 (7.3–30.9) | 5.6 (0.7–18.4) | <0.001 | 17.6 (15.0–20.7) | 6.85 (1.9–18.3) | 8.1 (3.3–17.2) | 16.3 (3.2–45.8) | 0.00 | 15.8 (14.6–17.1) | 6.0 (4.0–8.8) | 7.0 (4.1–11.5) | 4.9 (1.7–11.9) | <0.001 |
Very good | 43.3 (39.6–47.1) | 32.7 (25.8–40.4) | 47.2 (28.5–66.8) | 28.6 (17.4–43.2) | 47.9 (43.8–52.0) | 36.7 (26.2–48.6) | 64.1 (47.9–77.7) | 57.0 (35.3–76.4) | 39.2 (37.5–40.8) | 30.9 (26.5–35.6) | 24.4 (19.0–30.8) | 24.1 (16.3–34.0) | |||
Good | 31.4 (27.8–35.3) | 42.8 (34.8–51.2) | 29.4 (16.3–46.9) | 47.4 (31.9–63.4) | 26.6 (23.1–30.4) | 38.6 (28.0–50.4) | 19.6 (10.5–33.5) | 19.56 (9.1–36.6) | 31.2 (29.7–32.8) | 39.5 (34.8–44.4) | 48.2 (41.4–55.1) | 38.9 (29.4–49.3) | |||
Fair | 7.5 (5.6–10.1) | 18.0 (12.3–25.5) | 5.2 (2.0–11.8) | 17.3 (6.5–37.2) | 7.3 (5.3–9.9) | 17.1 (8.9–29.9) | 6.8 (1.9–17.9) | 6.7 (1.6–18.7) | 10.5 (9.5–11.6) | 18.2 (14.7–22.3) | 17.7 (13.0–23.6) | 22.2 (14.7–32.0) | |||
Poor | 0.7 (0.4–1.3) | 2.0 (0.5–5.9) | 2.2 (0.7–12.3) | 1.1 (0.4–6.4) | 0.5 (0.2–1.1) | 0.8 (0.2–2.6) | 1.4 (0.2–4.5) | 0.5 (0.2–3.1) | 3.3 (2.8–4.0) | 5.5 (3.6–8.3) | 2.8 (1.1–6.2) | 9.9 (5.1–18.1) | |||
Chronic illness b | |||||||||||||||
Yes | 29.3 (26.4–32.4) | 38.8 (31.5–46.5) | 55.2 (37.1–72.0) | 35.4 (20–54.5) | <0.001 | 32.1 (28.7–35.7) | 58.1 (46.4–68.9) | 40.3 (24.2–58.8) | 35.4 (19.0–56.1) | <0.01 | 49.2 (47.5–51.0) | 57.8 (52.9–62.6) | 61.9 (55.0–68.4) | 63.4 (53.0–72.7) | 0.001 |
No | 70.7 (67.6–73.6) | 61.2 (53.5–68.5) | 44.8 (28.0–62.9 | 64.6 (45.5–80) | 67.9 (64.3–71.4) | 41.9 (31.1–53.6) | 59.7 (41.2–75.8) | 64.6 (43.9–81.0) | 50.8 (49.1–52.5) | 42.2 (37.4–47.2) | 38.1 (31.6–45.0) | 36.6 (27.3–47.0) | |||
COVID-19–related outcomes | |||||||||||||||
Social-distancing c | |||||||||||||||
Yes | N = 1017 50.4 (46.4–54.3) | N = 97 35.7 (28.3–43.9) | N = 22 37.1 (19.7–58.7) | N = 19 24.1 (12.0–42.1) | <0.001 | N = 703 48.9 (44.8–53.0) | N = 73 33.6 (24.0–44.8) | N = 32 42.5 (26.1–60.7) | N = 19 38.2 (20.0–60.4) | 0.18 | N = 1832 54.8 (53.1–56.5) | N = 201 50.7 (45.8–55.6) | N = 113 58.0 (51.1–64.7) | N = 46 52.9 (42.6–62.9) | 0.29 |
No | N = 965 49.6 (45.7–53.6) | N = 177 64.3 (56.1–71.7) | N = 43 62.9 (41.3–80.4 | N = 62 76.0 (57.9–88.0) | N = 769 51.2 (47.0–55.2) | N = 109 66.4 (55.2–76.0) | N = 42 57.5 (39.3–73.9) | N = 28 61.8 (39.6–80.0) | N = 1493 45.2 (43.5–46.9) | N = 197 49.3 (44.4–54.2) | N = 90 42.0 (35.4–48.9) | N = 45 47.1 (37.1–57.4) | |||
Covid-19 Symptoms d | |||||||||||||||
Yes | N = 549 27.0 (24.1–30.1) | N = 91 29.9 (23.8–36.8) | N = 24 38.8 (21.2–59.9) | N = 28 24.5 (14.5–38.0) | 0.03 | N = 363 24.0 (20.5–27.8) | N = 52 34.5 (23.8–47.1) | N = 21 23.3 (12.6–38.8) | N = 15 24.0 (11.3–43.3) | 0.85 | N = 818 26.9 (25.4–28.5) | N = 108 28.0 (23.8–32.7) | N = 66 31.6 (25.6–38.3) | N = 23 36.2 (27.0–46.6) | 0.79 |
No | N = 1434 73.0 (69.9–75.9) | N = 183 70.2 (63.3–76.2) | N = 41 61.2 (40.1–78.8) | N = 53 75.5 (62.0–85.5) | N = 1114 76.0 (72.2–79.5) | N = 130 65.5 (52.9–76.2) | N = 53 76.7 (61.2–87.4) | N = 32 76.0 (56.7–88.7) | N = 2512 73.1 (71.6–74.6) | N = 290 72.0 (67.3–76.2) | N = 137 68.4 (61.7–74.4) | N = 68 63.8 (53.4–73.0) | |||
Covid-19 test e | |||||||||||||||
Yes | N = 35 1.8 (1.1–2.9) | N = 4 3.9 (0.4–13.7) | N = 1 10.0 (4.4–20.3) | N = 3 2.9 (0.2–12.4) | 0.60 | N = 55 4.2 (2.7–6.5) | N = 8 2.7 (1.1–5.9) | N = 1 3.2 (0.8–17.4) | N = 0 ― | 0.36 | N = 101 3.3 (2.7–4.0) | N = 13 3.0 (1.7–5.2) | N = 4 1.3 (0.2–4.2) | N = 5 12.3 (6.8–20.8) | 0.45 |
No | N = 1946 98.2 (97.1–98.9) | N = 270 96.1 (86.3–99.6) | N = 64 99.8 (99.0–99.9) | N = 78 97.1 (87.6–99.9) | N = 1420 95.8 (93.5–97.3) | N = 173 97.3 (94.1–98.9) | N = 73 96.8 (82.6–99.8) | N = 46 100 (―) | N = 3219 96.7 (96.0–97.3) | N = 383 97.0 (94.8–98.4) | N = 198 98.7 (95.8–99.8) | N = 86 87.8 (79.2–93.2) | |||
Covid-19 infection f | |||||||||||||||
Yes | N = 111 5.1 (3.91–6.7) | N = 22 6.9 (3.8–11.8) | N = 9 11.4 (4.7–23.7) | N = 9 10.0 (4.4–20.3) | <0.01 | N = 160 10.9 (8.6–13.8) | N = 18 9.0 (3.6–19.4) | N = 6 11.9 (1.8–37.4) | N = 7 20.4 (6.2–47.5) | 0.68 | N = 298 9.8 (8.8–10.8) | N = 35 8.1 (5.8–11.2) | N = 18 6.3 (3.6–10.7) | N = 11 17.5 (10.9–26.8) | 0.78 |
No | N = 1872 94.9 (93.3–96.1) | N = 252 93.2 (88.1–96.1) | N = 56 88.6 (76.3–95.3 | N = 72 90.0 (79.7–95.6) | N = 1317 89.1 (86.2–91.4) | N = 164 91.0 (80.6–96.4) | N = 68 88.1 (62.6–98.2) | N = 40 79.6 (52.5–93.9) | N = 3031 90.2 (89.2–91.2) | N = 363 91.9 (88.8–94.3) | N = 185 93.7 (89.3–96.4) | N = 80 82.5 (73.3–89.1) |
Weighted Percentages (%) with 95% Confidence Interval | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
National Child Development Study (NCDS), Born in 1958 (Aged 63) | Overall | |||||||||
(N = 4872) | (N = 13,077) | |||||||||
Non-Users | Cigarette | E-cigarette | Dual User | p-Value † | Non-Users | Cigarette | E-cigarette | Dual User | CMH χ2 †† | |
(N = 4313) | (N = 344) | (N = 147) | (N = 68) | (N = 11,103) | (N = 1198) | (N = 489) | (N = 287) | |||
Overall | 85.2 | 9.1 | 3.9 | 1.7 | 79.6 | 12.6 | 4.9 | 3 | ||
(84.2–86.2) | (8.4–10.0) | (3.4–4.5) | (1.4–2.2) | (78.9–80.3) | (12.0–13.2) | (4.5–5.3) | (2.7–3.3) | |||
Participant characteristics | ||||||||||
Gender | ||||||||||
Male | 50.2 | 55.2 | 51.9 | 47 | 0.69 | 48.7 | 50.6 | 55.8 | 54.7 | 0.01 |
(48.7–51.7) | (49.9–60.4) | (43.9–59.8) | (35.6–58.7) | (47.8–49.6) | (47.8–53.5) | (51.4–60.2) | (48.9–60.4) | |||
Female | 49.8 | 44.8 | 48.1 | 53.1 | 51.3 | 49.4 | 44.2 | 45.3 | ||
(48.3–51.3) | (39.6–50.1) | (40.2–56.1) | (41.4–64.4) | (50.4–52.3) | (46.5–52.2) | (39.8–48.6) | (39.6–51.1) | |||
Socioeconomic Class a | ||||||||||
High | 24.1 | 13.7 | 8.3 | 15.2 | <0.001 | 30.1 | 20.2 | 20.3 | 19.1 | <0.001 |
(22.8–25.4) | (10.4–17.8) | (4.7–14.0) | (8.4–25.8) | (29.3–31.0) | (18.0–22.6) | (17.0–24.1) | (14.9–24.1) | |||
Intermediate | 16 | 13.2 | 12.7 | 10.2 | 16.1 | 14.6 | 16.7 | 10.4 | ||
(15.0–17.2) | (10.0–17.3) | (8.2–19.2) | (4.7–19.9) | (15.4–16.8) | (12.7–16.7) | (13.6–20.3) | (7.3–14.5) | |||
Lower | 17.7 | 30.7 | 29 | 35.1 | 17.8 | 30.9 | 29.1 | 34.9 | ||
(16.6–18.9) | (26.0–35.8) | (22.3–36.9) | (24.8–47.0) | (17.1–18.5) | (28.4–33.6) | (25.2–33.3) | (29.6–40.6) | |||
Not classifiable § | 42.2 | 42.4 | 49.9 | 39.5 | 36 | 34.3 | 34 | 35.6 | ||
(40.7–43.6) | (37.2–47.7) | (42.0–57.9) | (28.8–51.4) | (35.1–36.9) | (31.7–37.1) | (29.9–38.3) | (30.2–41.3) | |||
Self-rated Health | ||||||||||
Excellent | 14.7 | 2 | 4.7 | 7.4 | <0.001 | 15.9 | 4.7 | 7.7 | 8 | <0.001 |
(13.7–15.8) | (0.9–4.2) | (2.1–9.6) | (2.8–16.5) | (15.2–16.6) | (3.7–6.1) | (5.7–10.5) | (5.3–11.7) | |||
Very good | 39.4 | 28.5 | 38 | 25.1 | 41.2 | 31.5 | 38 | 32.4 | ||
(37.9–40.8) | (23.9–33.5) | (30.6–46.1) | (16.2–36.6) | (40.2–42.1) | (28.9–34.2) | (33.8–42.4) | (27.2–38.0) | |||
Good | 32.2 | 37.9 | 37.2 | 33.6 | 31 | 39.6 | 37.7 | 36.4 | ||
(30.8–33.6) | (32.9–43.2) | (29.8–45.2) | (23.5–45.5) | (30.2–31.9) | (36.9–42.4) | (33.5–42.1) | (31.0–42.1) | |||
Fair | 11.4 | 22.5 | 14.1 | 31.3 | 9.9 | 19.1 | 13.1 | 19.6 | ||
(10.5–12.4) | (18.4–27.3) | (9.3–20.7) | (21.5–43.1) | (9.3–10.5) | (17.0–21.5) | (10.4–16.4) | (15.3–24.6) | |||
Poor | 2.4 | 9.1 | 6 | 2.6 | 2.1 | 5 | 3.4 | 3.8 | ||
(1.9–2.9) | (6.4–12.7) | (3.0–11.2) | (0.1–10.3) | (1.8–2.4) | (3.9–6.4) | (2.1–5.5) | (2.0–6.8) | |||
Chronic illness b | ||||||||||
Yes | 62.1 | 69 | 66.9 | 66.6 | 0.48 | 48.6 | 57.1 | 58.9 | 50.2 | <0.001 |
(60.6–63.6) | (63.9–73.7) | (58.9–74.1) | (54.7–76.7) | (47.6–49.5) | (54.2–59.9) | (54.5–63.2) | (44.4–56.1) | |||
No | 37.9 | 31 | 33.1 | 33.4 | 51.5 | 42.9 | 41.1 | 49.8 | ||
(36.4–39.4) | (26.3–36.2) | (25.9–41.1) | (23–45.3) | (50.5–52.4) | (40.1–45.8) | (36.8–45.5) | (43.9–55.6) | |||
COVID-19–related outcomes | ||||||||||
Social-distancing c | ||||||||||
Yes | N = 2700 | N = 204 | N = 86 | N = 45 | 0.43 | N = 6260 | N = 575 | N = 253 | N = 129 | <0.001 |
64 | 61.8 | 52.1 | 60 | 56.9 | 47.9 | 50.9 | 42.8 | |||
(62.6–65.4) | (56.5–66.8) | (44.1–60.0) | (48.1–70.8) | (55.9–57.8) | (45.1–50.8) | (46.4–55.3) | (37.2-48.6) | |||
No | N = 1606 | N = 139 | N = 61 | N = 23 | N = 4843 | N = 623 | N = 236 | N=158 | ||
36 | 38.2 | 47.9 | 40 | 43.1 | 52.1 | 49.1 | 57.2 | |||
(34.6–37.5) | (33.2–43.5) | (40.0–56.0) | (29.2–51.9) | (42.2–44.1) | (49.2–54.9) | (44.7–53.6) | (51.4-62.8) | |||
Covid-19 Symptoms d | ||||||||||
Yes | N = 946 | N = 89 | N = 31 | N = 22 | 0.08 | N = 2676 | N = 340 | N = 142 | N = 88 | 0.02 |
23.1 | 25.7 | 20.6 | 41.4 | 25 | 28.8 | 28 | 31.3 | |||
(21.8–24.3) | (21.3–30.6) | (14.8–27.9) | (30.4–53.3) | (24.2–25.8) | (26.3–31.4) | (24.2–32.1) | (26.2–36.9) | |||
No | N = 3367 | N = 255 | N = 116 | N = 46 | N = 8427 | N = 858 | N = 347 | N = 199 | ||
77 | 74.3 | 79.4 | 58.6 | 75 | 71.2 | 72 | 68.7 | |||
(75.7–78.2) | (69.4–78.7) | (72.01–85.2) | (46.8–69.6) | (74.2–75.8) | (68.6–73.7) | (67.9–75.8) | (63.1–73.8) | |||
Covid-19 test e | ||||||||||
Yes | N = 81 | N = 5 | N = 3 | N = 3 | 0.45 | N = 288 | N = 30 | N = 11 | N = 12 | 0.73 |
2.7 | 0.8 | 1.4 | 7.5 | 2.9 | 2.6 | 1.5 | 5.9 | |||
(2.3–3.3) | (0.1–2.6) | (0.1–5.2) | (2.9–16.6) | (2.6–3.3) | (1.8–3.6) | (0.7–3.03) | (3.7–9.4) | |||
No | N = 4210 | N = 335 | N = 143 | N = 65 | N = 10,815 | N = 1168 | N = 478 | N = 275 | ||
97.3 | 99.2 | 98.6 | 92.5 | 97.1 | 97.4 | 98.5 | 94.1 | |||
(96.7–97.7) | (97.4–99.9) | (94.8–99.9) | (83.4–97.1) | (96.8–97.4) | (96.4–98.2) | (96.9–99.4) | (90.6–96.3) | |||
Covid-19 infection f | ||||||||||
Yes | N = 244 | N = 16 | N = 9 | N = 6 | 0.57 | N = 815 | N = 91 | N = 42 | N = 33 | 0.04 |
5.7 | 3.8 | 4.2 | 12.9 | 7.5 | 6.8 | 7.3 | 14.8 | |||
(5.1–6.5) | (2.1–6.4) | (1.8–8.9) | (6.7–23.1) | (7.0–8.0) | (5.5–8.4) | (5.3–10.0) | (11.2–19.5) | |||
No | N = 4068 | N = 328 | N = 138 | N = 62 | N = 10,288 | N = 1107 | N = 447 | N = 254 | ||
94.3 | 96.2 | 95.8 | 87.1 | 92.6 | 93.2 | 92.7 | 85.2 | |||
(93.6–95.0) | (93.6–97.9) | (91.1–98.2) | (76.9–93.4) | (92.0–93.03) | (91.6–94.5) | (90.0–94.7) | (80.5–88.9) |
Adjusted Odds Ratio (aOR) with 95% Confidence Interval | |||
---|---|---|---|
aOR | 95% CI | p-Value | |
Experiencing Covid-19 Symptoms a (N = 12,804) | |||
Non-smokers | Ref. | ||
Cigarette | 1.21 | 0.87–1.69 | 0.26 |
E-cigarette | 1.08 | 0.61–1.89 | 0.8 |
Dual Use | 1.41 | 0.79–2.54 | 0.25 |
Adhered to Social-distancing b (N = 12,785) | |||
Non-smokers | Ref. | ||
Cigarette | 0.72 | 0.63–0.92 | <0.01 |
E-cigarette | 0.82 | 0.62–1.09 | 0.17 |
Dual Use | 0.58 | 0.41–0.83 | <0.01 |
Confirmed/Suspected Covid-19 diagnosis c (N = 12,803) | |||
Non-smokers | Ref. | ||
Cigarette | 1.1 | 0.89–1.36 | 0.66 |
E-cigarette | 1.22 | 0.90–1.65 | 0.97 |
Dual Use | 2.15 | 1.15–4.05 | 0.02 |
Received Covid-19 test d (N = 12,785) | |||
Non-smokers | Ref. | ||
Cigarette | 1.05 | 0.75–1.48 | 0.75 |
E-cigarette | 0.85 | 0.48–1.50 | 0.16 |
Dual Use | 1.97 | 0.62–6.32 | 0.25 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chen, D.T.-H.; Kyriakos, C.N. Cigarette and E-Cigarettes Dual Users, Exclusive Users and COVID-19: Findings from Four UK Birth Cohort Studies. Int. J. Environ. Res. Public Health 2021, 18, 3935. https://doi.org/10.3390/ijerph18083935
Chen DT-H, Kyriakos CN. Cigarette and E-Cigarettes Dual Users, Exclusive Users and COVID-19: Findings from Four UK Birth Cohort Studies. International Journal of Environmental Research and Public Health. 2021; 18(8):3935. https://doi.org/10.3390/ijerph18083935
Chicago/Turabian StyleChen, Daniel Tzu-Hsuan, and Christina N. Kyriakos. 2021. "Cigarette and E-Cigarettes Dual Users, Exclusive Users and COVID-19: Findings from Four UK Birth Cohort Studies" International Journal of Environmental Research and Public Health 18, no. 8: 3935. https://doi.org/10.3390/ijerph18083935
APA StyleChen, D. T. -H., & Kyriakos, C. N. (2021). Cigarette and E-Cigarettes Dual Users, Exclusive Users and COVID-19: Findings from Four UK Birth Cohort Studies. International Journal of Environmental Research and Public Health, 18(8), 3935. https://doi.org/10.3390/ijerph18083935